Strengthening and diversifying our portfolio through multiple partnerships.

Uni-Bio Science proactively assesses opportunities to broaden its product offering through in-licensing innovative treatments from global pharmaceutical partners seeking to leverage our broad development, manufacturing, sales and marketing and infrastructure. Uni-Bio Science evaluates potential candidates that are indicated for diseases prevalent in the Chinese population and are at all stages of development and commercialisation, which complement its portfolio.

For more information on our partnering strategy please contact our Head of Business Development via [email protected]

Uni-Bio Science is the partner of choice in China for global pharmaceutical companies

Uni-Bio Science's partners include :

Business partnership

1 2 

Sales Partnership with CR Zizhu can potentially access 5 times the number of hospitals in a short period of time. China Resources Zizhu is granted the sole distribution and promotion rights of GeneSoft® and will include the drug within its existing hospital network in Mainland China. Relying on CR Zizhu’s strong track records in ophthalmology, this partnership can help Uni-Bio maintain a foothold in the competitive PRC market amid aggressive price reduction pressure.


Extension of R&D capability into small molecule drugs. On December 1st, 2016, Beijing Genetech, subsidiary of Uni-Bio Science Group entered into a strategic agreement to co-develop promising oral anti-diabetic drugs (OAD). Acarbose will be the first product developed together, both companies will explore development of another 2 to 3 OAD. Sun-Novo has strong development track record in China with 65 IND approvals, 2 NDA approvals for API, 2 NDA approvals for finished drug.

Assets Partnership


Strategic Alliance with LUQA in Co-promoting Drugs and Medical Devices for Dermatology. Uni-Bio Science and LUQA Pharmaceuticals will conduct co-promotion of selected dermatology products from both company’s current and future portfolio. One of the products is Stratederm™, a non-sticky, transparent silicone gel formulation for the treatment of scars.

In November 2015, Uni-Bio Science acquired exclusive global rights to manufacture and commercialise Mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co. Ltd.